妊娠期炎症性肠病女性使用生物制剂治疗不影响婴儿对疫苗的应答
基于美国多中心妊娠期炎症性肠病与新生儿结局登记处2007至2016年数据,179名女性完成疫苗调查(26名未暴露,153名暴露于生物制剂)。暴露组与未暴露组婴儿抗HiB保护性抗体比例(71% vs 50%,P=.41)及抗破伤风类毒素保护性抗体比例(80% vs 75%,P=.66)均无显著差异。结论认为宫内暴露于生物制剂似乎不影响婴儿至少7月龄时对HiB和破伤风疫苗的抗体应答。
要点
- 妊娠期生物制剂暴露组与未暴露组婴儿抗HiB保护性抗体比例无显著差异(71% vs 50%,P=.41)。
- 两组婴儿抗破伤风类毒素保护性抗体比例无显著差异(80% vs 75%,P=.66)。
- 脐血英夫利西单抗浓度与婴儿是否有保护性抗体滴度无显著相关。
核心结论
- 婴儿至少7月龄时测定的抗HiB和破伤风类毒素抗体滴度显示,宫内暴露于生物制剂似乎不影响疫苗应答。
研究设计与样本
- 基于美国多中心妊娠期炎症性肠病与新生儿结局登记处的数据,收集2007年至2016年妊娠女性资料。
- 对至少7月龄婴儿采集血清样本检测抗HiB或破伤风类毒素抗体滴度,母亲于2013年7月至2016年10月完成疫苗实践与结局调查。
- 对33名婴儿的脐血样本检测生物制剂浓度。
- 比较母亲暴露于生物制剂(英夫利西单抗、阿达木单抗、聚乙二醇化赛妥珠单抗、戈利木单抗、那他珠单抗、维得利珠单抗或乌司奴单抗,单药或联合免疫调节剂,受孕至分娩期间任意时间)与未暴露母亲的婴儿疫苗应答。
主要发现
- 共179名女性完成疫苗调查,其中26名未暴露于生物制剂,153名暴露于生物制剂。
- 暴露组婴儿抗HiB保护性抗体比例为71%(n=42),未暴露组为50%(n=8),差异无统计学意义(P=.41)。
- 暴露组婴儿抗破伤风类毒素保护性抗体比例为80%,未暴露组为75%,差异无统计学意义(P=.66)。
- 脐血英夫利西单抗中位浓度在有无抗HiB保护性抗体(P=.30)或抗破伤风类毒素保护性抗体(P=.93)的婴儿间无显著差异。
- 接受轮状病毒疫苗且母亲暴露于生物制剂的40名婴儿中,7名出现轻微反应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: In women with inflammatory bowel diseases (IBDs), exposure to immunomodulator or biologic therapy has not been associated with adverse events during pregnancy or outcomes of newborns. We investigated whether exposure of patients to these agents during pregnancy affects serologic responses to vaccines in newborns. METHODS: We collected data from the Pregnancy in IBD and Neonatal Outcomes registry, which records outcomes of pregnant women with diagnosis of IBD receiving care at multiple centers in the United States, from 2007 through 2016. Serum samples collected from infants at least 7 months old were analyzed for titers of antibodies to Haemophilus influenzae B (HiB) or tetanus toxin; mothers completed a survey of vaccine practices and outcomes from July 2013 through October 2016. Umbilical cord blood samples from 33 infants were assayed for concentration of biologic agents. Vaccination response was compared between infants born to mothers exposed to biologic therapy (infliximab, adalimumab, certolizumab pegol, golimumab, natalizumab, vedolizumab, or ustekinumab-either as a single agent or in combination with an immunomodulator, at any time between conception and delivery) and infants born to unexposed mothers. RESULTS: A total of 179 women completed the vaccine survey (26 biologic unexposed, 153 exposed to a biologic agent). We found no significant difference in proportions of infants with protective antibody titers against HiB born to exposed mothers (n = 42, 71%) vs unexposed mothers (n = 8, 50%) (P = .41). We also found no difference in the proportion of infants with protective antibody titers to tetanus toxoid born to exposed mothers (80%) vs unexposed mothers (75%) (P = .66). The median concentration of infliximab in cord blood did not differ significantly between infants with vs without protective antibody titers to HiB (P = .30) or tetanus toxoid (P = .93). Mild reactions were observed in 7/40 infants who received rotavirus vaccine and whose mothers had been exposed to biologic therapies. CONCLUSIONS: Vaccination of infants against HiB and tetanus toxin, based on antibody titers measured when infants were at least 7 months old, does not appear to be affected by in utero exposure to biologic therapy.
引用
- Beaulieu DB, Ananthakrishnan AN, Martin C, et al. Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines. Clin Gastroenterol Hepatol. 2017. PMID: 28870657. doi:10.1016/j.cgh.2017.08.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。